Burlington, ON – May 5, 2004, The Jenex Corporation, a company which developed its proprietary patented thermal therapeutic device for the prevention of cold sores, is now listed on the Frankfurt Stock Exchange (the “DAX”) in Germany under the symbol JNX, code number 694434. The Company’s primary listing continues to be on the TSX- Venture Exchange (the “TSXV”) and in addition to the Frankfurt Exchange listing, the Company also has a secondary listing on the Berlin-Bremin Stock Exchange.

Michael Jenkins, President and CEO of Jenex said, “Jenex is very pleased to have achieved a listing on The Frankfurt Stock Exchange, which is the world’s third largest in terms of volume of shares traded. With the planned launch of our cold sore device in late 2004 in Canada and the European markets throughout 2005, foreign investors will become informed of Jenex and its` cold sore prevention device. This listing on the DAX gives the Company greater access to the large German and European institutional and retail markets.”

About The Jenex Corporation:

Headquartered in Burlington, Ontario, the Corporation has developed and patented a thermal therapeutic device for the prevention of cold sores. Patents in fifteen countries, including the United States, Canada, Australia, and Europe protect the technology. The Corporation is preparing to launch its cold sore prevention device in the Canadian market in late 2004. Jenex has clearance to market their cold sore prevention device OTC (over-the counter) in Canada, with its approved claim, “For prevention and relief of the symptoms of herpes labialis (cold sores), such as blistering, lesions, inflammation, and discomfort. Also helps alleviate the embarrassment that is typically associated with herpes labialis (cold sore) outbreaks”. Regulatory approvals are being pursued for USA, Europe and Australia. It is estimated that there are between 50 and 100 million recurrent cold sore sufferers in North America alone. As the only product clinically proven to prevent the outbreak of cold sores, the Corporation's thermal therapy product has the potential to dominate a large and underdeveloped market.  More information about the Corporation can be found at www.jenexcorp.com.

Forward Looking Statements

The TSX Venture Exchange Inc. has not reviewed and does not accept responsibility for the accuracy or the contents of this press release.  Certain information included in this press release is forward-looking and is subject to important risks and uncertainties. The results or events predicted in these statements may differ materially from actual results or events.

For further information, please contact:

The Jenex Corporation
Michael Jenkins - President
Phone:  905-632-3830
Email:  jenex@sprint.ca
Fax:  905-632-3774
940 Sheldon Court, Suite 207
Burlington, Ontario Canada
L7L 5K6